Institution

EMD Serono Research & Development Institute

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 17, 2026 · PHASE 1 TRIAL

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

ClinicalTrials.gov

This is a first-in-human Phase 1 trial registration with no results posted; the study is actively recruiting and has not yet reported safety, tolerability, or efficacy outcomes.

PreliminaryM7437 EMD Serono Research & Development Institute Advanced Solid Tumors

Reported

PhasePhase 1

Planned enrollment138

DLT observation period21 days (cycle 1)

AUG 11, 2026 · PHASE 1 TRIAL

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

ClinicalTrials.gov

First-in-human Phase 1 study with no results posted; designed to establish safety, tolerability, and recommended dose rather than to prove efficacy.

PreliminaryEMD Serono Research & Development Institute M0324 Advanced Solid Tumor

Reported

Estimated enrollment77

Study phasePhase 1

Primary outcome (Parts 1 and 2)Number of Participants With Dose Limiting T…